feed,title,long_url,short_url
Benzinga,"Despite FDA Doubts, Adcomm Backs Alnylam's Gene Silencing Therapy For Expanded Use Into Rare Heart Disease",https://benzinga.com/general/biotech/23/09/34571780/despite-fda-doubts-adcomm-backs-alnylams-gene-silencing-therapy-for-expanded-use-into-rare-heart-,https://da.gd/F3O6d
